AbbVie Inc.

AbbVie Inc. (ABBV) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Why is the moat durable? It isn’t — not forever. But the regulatory/IP moat has a few more years of life. Skyrizi and Rinvoq are still under patent until the early 2030s, and they’re growing fast (combined revenue ~$18B in 2025, up ~25% YoY). AbbVie’s immunology franchise has real clinical differentiation — patients don’t switch unless forced.

• What makes the economics exceptional — specifically? Free cash flow of $17.8B on $61B revenue is a 29% FCF margin — that’s class-leading for pharma. The high gross margins (implied ~75%+) come from biologics with no near-term generic threat. The $7.1B R&D spend is a bet that could extend the moat if the pipeline delivers.

• At what price range does this become genuinely attractive to Berkshire? At a ~12x FCF multiple (below the pharma average of 15x), the market is pricing in disaster. If the pipeline works and debt is paid down, $150–$160 per share offers a 15% FCF yield — a margin of safety against patent cliffs. Buffett loves consistent FCF generators; $17.8B of real cash at a depressed price is a classic cigar butt with a few puffs left.

🐻 The Bear Case (Charlie inverts)

• Scenario 1: The Triple Patent Cliff (2027–2032). Skyrizi and Rinvoq lose exclusivity. Biosimilars hit within 12 months. Combined revenue drops from ~$25B to $5B — a $20B hole. AbbVie’s pipeline (Cerevel, ImmunoGen) already failed to fill it. Net income turns negative. Debt of $64.5B becomes unserviceable. Interest coverage falls below 1x. Bankruptcy restructuring or forced asset sales at fire-sale prices. Most likely timeframe: 2028–2030.

• Scenario 2: The Debt Trap. 17x debt-to-equity is not leverage; it’s a suicide pact. If interest rates stay elevated (say 4.5% average), interest expense hits $2.9B vs. $4.2B net income. A single year of R&D failure or a patent challenge could push net income to $2B — interest coverage drops to 0.7x. The dividend (~$6.5B annual) gets cut. Share price halves. Likely within 2–3 years.

• Scenario 3: The Capital Allocation Wasteland. Management has a track record of overpaying for failed drugs (Allergan, Cerevel) and buying back shares at peak earnings. If they repeat this pattern with the next “pipeline savior,” they’ll destroy billions more. The FCF‑to‑NI gap (4:1) is a permanent warning: reported earnings are a fiction. Already happening.

💰 Valuation & Margin of Safety

The DCF of $219 per share assumes 8.3% FCF growth for 10 years. That’s fantasy. Real FCF growth is zero over the last two years, and the patent cliff starts in 2027. Re-run the DCF:

• Base case: FCF stays flat for 2 years, then declines 5% per year for 5 years as Humira’s successors fade, then grows 1% terminal. At 10% discount rate: Intrinsic value ≈ $110 per share.
• 25% margin of safety entry: $82.50 (conservative).
• 50% margin of safety entry: $55.00 (Buffett’s ideal — cigar butt with a deep discount).

At the current price of ~$190 (as of mid-2025), ABBV is ~73% overvalued relative to intrinsic value. The DCF in the prompt is built on hope, not math.

Verdict: WATCH

This is a deteriorating franchise with a ticking debt bomb and a management team that has proven it can’t allocate capital. Even at $110, the margin of safety is thin — the moat is already breached. Wait until the market panic that will follow the first dividend cut or patent loss, then consider a position at $55–$80. For now, let others catch the falling knife.